PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare treatment with oral Paxlovid
(nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent
long-COVID (post-COVID-19 condition) in adults aged 18-64 years old.
The main question it aims to answer is:
Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared
to placebo.
Participants with acute COVID-19, documented with positive lateral flow test or PCR, within
the last 5 days will be randomised to take either Paxlovid or placebo. All participants will
receive standard of care in addition. Participants will respond to electronic questionnaires
at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at
3 months follow-up.
Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid
treatment can prevent the occurrence of long-COVID.